Consistent up-regulation of Stat3 independently of Jak2 mutations in a new murine model of essential thrombocythemia

Cancer Research

Volumn 69, Issue 1, 2009, Pages 262-271

  Senyuk, Vitalyi ^a   Rinaldi, Ciro Roberto ^a,c   Li, Donglan ^a   Cattaneo, Francesca ^a   Stojanovic, Aleksandra ^a   Pane, Fabrizio ^c   Du, Xiaoping ^a   Mahmud, Nadim ^a   Dickstein, Jerome ^b   Nucifora, Giuseppina ^a,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; STAT3 PROTEIN; VIRUS DNA;

ADULT; AGED; AML1 GENE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 3; DEGRANULATION; DISEASE MODEL; EV11 GENE; GENE FUSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LATENT PERIOD; MDS1 GENE; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE SHAPE; THROMBOCYTHEMIA;

AGED; ANIMALS; BLOOD PLATELETS; BONE MARROW CELLS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUMANS; JANUS KINASE 2; K562 CELLS; MEGAKARYOCYTES; MICE; MICE, INBRED C57BL; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; STAT3 TRANSCRIPTION FACTOR; THROMBOCYTHEMIA, ESSENTIAL; UP-REGULATION;

EID: 58249116533     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2534     Document Type: Article

References (53)

1. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
2. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007;6:550-66.
3. Epstein E, Goedel A. Hammorhagische thrombocythamie bei vascularer schrumpfmilz. Virch Arch Pathol Anat 1934;292:233.
4. Gunz FW. Hemorrhagic thrombocythemia: a critical review. Blood 1960;15:706-23.
5. Ozer FL, Truax WE, Miesch DC, Levin WC. Primary hemorrhagic thrombocythemia. Am J Med 1960;26:807-23.
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
7. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005;434:1144-48.
8. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
9. Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D. t(3;21)(q26;q22) in myeloid leukemia. Cancer 2006;106:1730-8.
10. Rubin CM, Larson RA, Bitter MA, et al. Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia. Blood 1987;70:1338-42.
11. Nucifora G, Birn DJ, Espinosa R III, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 1993;81:2728-34.
12. Nucifora G, Begy KR, Kobayashi H, et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci U S A 1994;91:4004-8.
13. Senyuk V, Chakraborty S, Mikhail FM, Zhao R, Chi Y, Nucifora G. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. Oncogene 2002;21:3232-40.
14. Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci U S A 2000;97:10984-9.
15. Forsberg EC, Serwold T, Kogan S, Weissman IL, Passegué E. New evidence supporting megakaryocyte-erythrocyte potential of flk2/flt3+ multipotent hematopoietic progenitors. Cell 2006;126:415-26.
16. 2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 2003;278:30725-31.
17. Senyuk V, Sinha KK, Li D, Rinaldi CR, Yanamandra S, Nucifora G. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis. Cancer Res 2007;67:5658-66.
18. Kouskouti A, Scheer E, Staub A, Tora L, Talianidis I. Gene-specific modulation of TAF10 function by SET9-mediated methylation. Mol Cell 2004;14:175-82.
19. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994;1:136-8.
20. Thiele J, Kvasnicka HM, Schmitt-Graeff A. Acute panmyelosis with myelofibrosis. Leuk Lymph 2004;45:681-7.
21. Cashell AW, Buss DH. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states. Ann Hematol 1992;64:273-6.
22. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993;43:1107-10.
23. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006;32:174-207.
24. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 2002;108:55-65.
25. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997;90:4031-8.
26. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Practice Res Clin Haematol 2006;19:617-33.
27. Bermejo E, Alberto MF, Meschengieser SS, Lazzari MA. Assessment of platelet activation in myeloproliferative disorders with complementary techniques. Blood Coagul Fibrinolysis 2004;15:235-40.
28. Cesar JM, de Miguel D, García Avello A, Burgaleta C. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100. Am J Clin Pathol 2005;123:772-7.
29. Kobusiak-Prokopowicz M, Kuliczkowski W, Karolko B, Prajs I, Mazurek W. Platelet aggregation and P-selectin levels during exercise treadmill test in patients with ischaemic heart disease. Kardiol Pol 2006;64:1094-100.
30. Petrides PE, Siegel F. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Blood Cells Mol Dis 2006;36:379-84.
31. Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006;96:781-8.
32. Kiuchi N, Nakajima K, Ichiba M, et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999;189:63-73.
33. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999;11:709-19.
34. Goerttler PS, Steimle C, März E, et al. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patient. Blood 2005;106:2862-4.
35. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006;66:11156-65.
36. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108:1652-60.
37. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617Fcauses a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274-81.
38. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC. Ratio of mutant JAK2-617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008;111:3931-40.
39. Cuenco GM, Nucifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci U S A 2000;97:1760-5.
40. Zhang S, Ramsay ES, Mock BA. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc Natl Acad Sci U S A 1998;95:2429-34.
41. Ertenli I, Kiraz S, Oztürk MA, Haznedaroǧlu I, Celik I, Calgüneri M. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int 2003;23:49-60.
42. Jenkins BJ, Roberts AW, Greenhill CJ, et al. Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 2007;109:2380-8.
43. Chatti K, Farrar WL, Duhé RJ. Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry 2004;43:4272-83.
44. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006;6:602-12.
45. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005;65:939-47.
46. Teofili L, Martini M, Cenci T, et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617FJAK-2 mutation. Blood 2007;110:354-9.
47. Schwemmers S, Will B, Waller CF, et al. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol 2007;35:1695-703.
48. Maki K, Yamagata T, Asai T, et al. Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos. Blood 2005;106:2147-55.
49. Elagib KE, Goldfarb AN. Regulation of RUNX1 transcriptional function by GATA-1. Crit Rev Eukaryot Gene Expr 2007;17:271-80.
50. Kostyak JC, Naik UP. Megakaryopoiesis: transcriptional insights into megakaryocyte maturation. Front Biosci 2007;12:2050-62.
51. Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-β-mediated growth inhibition of myeloid cells. Blood 1998;92:4003-12.
52. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G. MDS1/EVI1 enhances TGF- β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF- β1. Leukemia 1999;13:348-57.
53. Kuroda H, Matsunaga T, Terui T, et al. Decrease of Smad4 gene expression in patients with essential thrombocythaemia may cause an escape from suppression of megakaryopoiesis by transforming growth factor-β1. Br J Haematol 2004;124:211-20.